Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/121735
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSrand, Vibeke-
dc.contributor.authorLevy, Roger A.-
dc.contributor.authorCervera i Segura, Ricard, 1960--
dc.contributor.authorPetri, Michelle A.-
dc.contributor.authorBirch, Helen-
dc.contributor.authorFreimuth, William W.-
dc.contributor.authorZhong, Z.John-
dc.contributor.authorClarke, Ann E.-
dc.contributor.authorBLISS-52 and -76 Study Groups-
dc.date.accessioned2018-04-20T09:52:02Z-
dc.date.available2018-04-20T09:52:02Z-
dc.date.issued2014-03-22-
dc.identifier.issn0003-4967-
dc.identifier.urihttp://hdl.handle.net/2445/121735-
dc.description.abstractOBJECTIVE: Assess the effects of belimumab treatment plus standard systemic lupus erythematosus (SLE) therapy on health-related quality of life (HRQOL) in patients with active, autoantibody-positive SLE. METHODS: Patients received standard therapy plus placebo or belimumab 1 or 10 mg/kg in two multicentre, randomised controlled trials of 52 (BLISS-52; N=865) and 76 (BLISS-76; N=819) weeks' duration. Responders were evaluated by SLE Responder Index at week 52. Patient-reported outcome assessments included SF-36, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, and EQ-5D. RESULTS: Mean SF-36 Physical Component Summary (PCS) scores at week 24 was a major secondary endpoint. Baseline SF-36 scores were 1.5 SDs below age-/sex-matched US norms with similar improvement at week 24 across treatment groups. Mean changes from baseline in PCS scores were significantly (p<0.05) greater with belimumab 1 mg/kg (4.20) and 10 mg/kg (4.18) versus placebo (2.96) in BLISS-52, week 52. In BLISS-76, significantly (p<0.05) greater improvements were seen with belimumab 1 mg/kg in PCS (belimumab 1 mg/kg=4.37, 10 mg/kg=3.41 vs placebo=2.85) and Mental Component Summary (MCS) scores (belimumab 1 mg/kg=3.14, 10 mg/kg=2.70 vs placebo=1.40) at week 52, and in MCS score at week 76 (belimumab 1 mg/kg=3.05, 10 mg/kg=2.28 vs placebo=1.36). In pooled analysis, significantly greater improvements in PCS, SF-36 vitality domain, and FACIT-Fatigue scores at week 52 were evident with both belimumab doses. CONCLUSIONS: The clinically meaningful improvements in HRQOL in autoantibody-positive patients with active SLE treated with belimumab and standard therapy are consistent with the reductions in disease activity observed in these trials.-
dc.format.extent7 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBMJ Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2012-202865-
dc.relation.ispartofAnnals of the Rheumatic Diseases, 2014, vol. 73, num. 5, p. 838-844-
dc.relation.urihttps://doi.org/10.1136/annrheumdis-2012-202865-
dc.rights(c) BMJ Publishing Group, 2014-
dc.subject.classificationLupus eritematós-
dc.subject.classificationMalalties autoimmunitàries-
dc.subject.classificationTractament del dolor-
dc.subject.classificationQualitat de vida-
dc.subject.otherLupus erythematosus-
dc.subject.otherAutoimmune diseases-
dc.subject.otherPain treatment-
dc.subject.otherQuality of life-
dc.titleImprovements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec643131-
dc.date.updated2018-04-20T09:52:02Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid23524886-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
643131.pdf1.06 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.